Updated

An FDA advisory panel cautiously recommended approval of Grail's Galleri blood test, which the company says can detect up to 50 forms of cancer, marking a potential first for multi-cancer early detection screening. If approved, the test could mark a major shift in cancer screening practice, though experts continue to debate the strength of the supporting evidence.